Amrutanjan Health Care Limited (AMRUTANJAN.BO)
INR 749.5
(-0.43%)
INR 749.5
(-0.43%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.55 Billion INR | -21.21% |
| 2022 | 1.97 Billion INR | -12.36% |
| 2021 | 2.25 Billion INR | 17.19% |
| 2020 | 1.92 Billion INR | 33.9% |
| 2019 | 1.43 Billion INR | 7.94% |
| 2018 | 1.33 Billion INR | 8.28% |
| 2017 | 1.22 Billion INR | -1.07% |
| 2016 | 1.24 Billion INR | 4.24% |
| 2015 | 1.19 Billion INR | 14.8% |
| 2014 | 1.03 Billion INR | 22.53% |
| 2013 | 847.23 Million INR | 9.33% |
| 2012 | 774.93 Million INR | -0.8% |
| 2011 | 781.18 Million INR | 25.69% |
| 2010 | 621.53 Million INR | 7.48% |
| 2009 | 578.28 Million INR | 7.68% |
| 2008 | 537.05 Million INR | 18.76% |
| 2007 | 452.2 Million INR | -0.87% |
| 2006 | 456.15 Million INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 242.82 Million INR | -50.78% |
| 2023 Q3 | 467.95 Million INR | -3.31% |
| 2023 Q1 | 372.52 Million INR | -24.16% |
| 2023 FY | 1.55 Billion INR | -21.21% |
| 2023 Q2 | 483.97 Million INR | 29.92% |
| 2023 Q4 | 493.33 Million INR | 5.42% |
| 2022 Q4 | 491.2 Million INR | -11.82% |
| 2022 Q1 | 359.65 Million INR | -35.9% |
| 2022 Q2 | 567.65 Million INR | 57.83% |
| 2022 FY | 1.97 Billion INR | -12.36% |
| 2022 Q3 | 557.06 Million INR | -1.87% |
| 2021 Q4 | 561.06 Million INR | -12.18% |
| 2021 FY | 2.25 Billion INR | 17.19% |
| 2021 Q1 | 444.08 Million INR | -14.96% |
| 2021 Q2 | 605.73 Million INR | 36.4% |
| 2021 Q3 | 638.91 Million INR | 5.48% |
| 2020 Q1 | 252.87 Million INR | -29.75% |
| 2020 Q4 | 522.17 Million INR | -12.94% |
| 2020 Q3 | 599.77 Million INR | 11.32% |
| 2020 Q2 | 538.8 Million INR | 113.07% |
| 2020 FY | 1.92 Billion INR | 33.9% |
| 2019 Q2 | 408.54 Million INR | 102.45% |
| 2019 Q4 | 359.94 Million INR | -22.79% |
| 2019 Q3 | 466.16 Million INR | 14.1% |
| 2019 Q1 | 201.8 Million INR | -55.69% |
| 2019 FY | 1.43 Billion INR | 7.94% |
| 2018 Q1 | 177.84 Million INR | -56.92% |
| 2018 FY | 1.33 Billion INR | 8.28% |
| 2018 Q4 | 455.45 Million INR | 23.07% |
| 2018 Q3 | 370.08 Million INR | 13.05% |
| 2018 Q2 | 327.37 Million INR | 84.08% |
| 2017 Q2 | 328.71 Million INR | 100.92% |
| 2017 FY | 1.22 Billion INR | -1.07% |
| 2017 Q3 | 369.95 Million INR | 12.54% |
| 2017 Q4 | 412.85 Million INR | 11.6% |
| 2017 Q1 | 163.61 Million INR | -58.3% |
| 2016 Q3 | 387.27 Million INR | 6.71% |
| 2016 Q2 | 362.93 Million INR | 0.0% |
| 2016 FY | 1.24 Billion INR | 4.24% |
| 2016 Q4 | 392.38 Million INR | 1.32% |
| 2015 FY | 1.19 Billion INR | 14.8% |
| 2014 FY | 1.03 Billion INR | 22.53% |
| 2013 FY | 847.23 Million INR | 9.33% |
| 2012 Q2 | 158.64 Million INR | 98.12% |
| 2012 Q3 | 224.2 Million INR | 41.33% |
| 2012 Q4 | 302.11 Million INR | 34.75% |
| 2012 FY | 774.93 Million INR | -0.8% |
| 2012 Q1 | 80.07 Million INR | 0.0% |
| 2011 FY | 781.18 Million INR | 25.69% |
| 2010 FY | 621.53 Million INR | 7.48% |
| 2009 FY | 578.28 Million INR | 7.68% |
| 2008 FY | 537.05 Million INR | 18.76% |
| 2007 FY | 452.2 Million INR | -0.87% |
| 2006 FY | 456.15 Million INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Ajanta Pharma Limited | 21.06 Billion INR | 92.61% |
| Sigachi Industries Limited | 2 Billion INR | 22.262% |
| Bal Pharma Limited | 770.19 Million INR | -102.096% |
| Ind-Swift Laboratories Limited | 6.19 Billion INR | 74.872% |
| Medico Remedies Limited | 262.14 Million INR | -493.77% |
| Lasa Supergenerics Limited | 121.02 Million INR | -1186.071% |
| Venus Remedies Limited | 2.18 Billion INR | 28.684% |
| Sun Pharma Advanced Research Company Limited | -602.4 Million INR | 358.386% |
| Alpa Laboratories Limited | 188.89 Million INR | -724.02% |
| Nectar Lifesciences Limited | 2.97 Billion INR | 47.628% |
| Shilpa Medicare Limited | 3.54 Billion INR | 56.115% |
| Aarti Drugs Limited | 8.31 Billion INR | 81.283% |
| Lupin Limited | 123.71 Billion INR | 98.742% |
| Aurobindo Pharma Limited | 154.68 Billion INR | 98.994% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 98.757% |
| Windlas Biotech Limited | 1.33 Billion INR | -16.263% |
| Suven Life Sciences Limited | -200.79 Million INR | 875.177% |
| Eris Lifesciences Limited | 10.42 Billion INR | 85.072% |
| Valiant Laboratories Limited | -60.66 Million INR | 2665.825% |
| J. B. Chemicals & Pharmaceuticals Limited | 22.69 Billion INR | 93.143% |
| Solara Active Pharma Sciences Limited | 861.2 Million INR | -80.74% |
| Ipca Laboratories Limited | 29.8 Billion INR | 94.778% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | 57.88% |
| Achyut Healthcare Limited | 4.86 Million INR | -31920.819% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 99.398% |
| Bajaj HealthCare Limited | 1.47 Billion INR | -5.757% |
| RPG Life Sciences Limited | 2.48 Billion INR | 37.312% |
| Mankind Pharma Limited | 44.52 Billion INR | 96.504% |
| Laurus Labs Limited | 24.62 Billion INR | 93.678% |
| Piramal Pharma Limited | 24.47 Billion INR | 93.639% |
| Syncom Formulations (India) Limited | 942.39 Million INR | -65.167% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 96.671% |
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 94.188% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 97.755% |
| Unichem Laboratories Limited | 4.86 Billion INR | 68.005% |
| Sequent Scientific Limited | 2.97 Billion INR | 47.745% |
| Novartis India Limited | 1.32 Billion INR | -17.306% |
| Wanbury Limited | 1.73 Billion INR | 10.06% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | 62.25% |
| Wockhardt Limited | 16.24 Billion INR | 90.415% |
| Themis Medicare Limited | 1.5 Billion INR | -3.499% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | -138.516% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 92.076% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | 87.481% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 99.049% |
| Divi's Laboratories Limited | 32.44 Billion INR | 95.202% |
| NATCO Pharma Limited | 25.73 Billion INR | 93.952% |
| Gufic Biosciences Limited | 4.16 Billion INR | 62.653% |
| IOL Chemicals and Pharmaceuticals Limited | 4.58 Billion INR | 66.021% |
| Ind-Swift Limited | 2.17 Billion INR | 28.354% |
| Procter & Gamble Health Limited | 5.78 Billion INR | 73.077% |
| FDC Limited | 8.33 Billion INR | 81.325% |
| Krebs Biochemicals & Industries Limited | 192.72 Million INR | -707.636% |
| Granules India Limited | 16.79 Billion INR | 90.735% |
| Medicamen Biotech Limited | 495.49 Million INR | -214.137% |
| Alkem Laboratories Limited | 52.29 Billion INR | 97.024% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | 74.986% |
| Biofil Chemicals and Pharmaceuticals Limited | 14.57 Million INR | -10576.022% |
| Brooks Laboratories Limited | 65.62 Million INR | -2272.039% |
| Megasoft Limited | 342.07 Million INR | -355.032% |
| ZIM Laboratories Limited | 1.26 Billion INR | -22.863% |
| Strides Pharma Science Limited | 14.38 Billion INR | 89.182% |
| Neuland Laboratories Limited | 8.24 Billion INR | 81.128% |
| Morepen Laboratories Limited | 6.16 Billion INR | 74.737% |
| Hikal Limited | 3.14 Billion INR | 50.477% |
| Indoco Remedies Limited | 6.04 Billion INR | 74.235% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | 73.308% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | -150.861% |
| Mangalam Drugs & Organics Limited | 703.6 Million INR | -121.222% |
| Hester Biosciences Limited | 1.27 Billion INR | -22.21% |